Key statistics
On Thursday, C4 Therapeutics Inc (CCCC:NSQ) closed at 4.01, 278.30% above the 52 week low of 1.06 set on Dec 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.03 |
---|---|
High | 4.32 |
Low | 3.89 |
Bid | 3.96 |
Offer | 4.10 |
Previous close | 4.05 |
Average volume | 1.07m |
---|---|
Shares outstanding | 70.59m |
Free float | 62.52m |
P/E (TTM) | -- |
Market cap | 285.89m USD |
EPS (TTM) | -1.70 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
- C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
- C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
- C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
- C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
- C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
- C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
- C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
More ▼